자료실

백신실용화기술개발사업단의 관련한 자료를 받을 수 있습니다.

국내외 동향

제목 [보고서] [한국보건산업진흥원] 프리미엄백신 개발전략 연구 221107
  • 작성자 관리자
  • 작성일 2022-11-25
  • 조회수 62
첨부파일

제1장. 서 론 ······················································································1
1. 연구의 필요성과 목적 ······································································2
2. 연구 구성 ···························································································3
3. 연구 방법 ···························································································4
4. 연구 대상 ···························································································8

제2장. 프리미엄 백신 시장 분석 ·····················································9
1. 프리미엄 백신이란? ········································································10
2. 프리미엄 백신 개발 기업 ······························································15
3. 폐렴구균 백신 시장 ········································································20
4. 대상포진 백신 시장 ········································································26
5. 자궁경부암 백신 시장 ····································································34
6. 로타바이러스 백신 시장 ································································41

제3장. 프리미엄 백신 개발과정 분석 ············································48
1. 폐렴구균 백신 ·················································································49
2. 대상포진 백신 ·················································································77
3. 자궁경부암 백신 ··············································································91
4. 로타바이러스 백신 ········································································112

제4장. 가치사슬별 기술혁신과 성공요인 ····································125
1. 백신 가치사슬 단계별 특성 분석 ···············································126
2. 프리미엄 백신 개발의 성공 요인 ···············································142

제5장. 결론 및 정책 제언 ····························································150
1. 우리나라 백신산업의 현황 ··························································151
2. 백신산업 육성을 위한 과제 ························································153
3. 연구의 한계와 후속 연구 ····························································170

 

출처: 한국보건산업진흥원

 

이전글 [글로벌 보건산업 동향 Vol.454] 바이오시밀러, R&D 제고 방안 221121
다음글 [한국바이오협회] 백신 주권을 위한 길 221123